主要文件

查看所有文档

Y0000500

阿卡波糖

Name: 阿卡波糖
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

阿卡波糖, 4",6"-二脱氧-4"-([1S]-[1,4,6/5]-4,5,6-三羟基-3-羟甲基-2-环己烯基氨基)-麦芽三糖

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₅H₄₃NO₁₈

化学文摘社编号:

56180-94-0

分子量:

645.60

NACRES:

NA.24

PubChem Substance ID:

329830985

UNSPSC Code:

41116107

MDL number:

MFCD00869592

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

agency

EP Reference Standard

API family

acarbose

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

C[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]2CO)O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]1N[C@H]4C=C(CO)[C@@H](O)[C@H](O)[C@H]4O

InChI

1S/C25H43NO18/c1-6-11(26-8-2-7(3-27)12(30)15(33)13(8)31)14(32)19(37)24(40-6)43-22-10(5-29)42-25(20(38)17(22)35)44-21-9(4-28)41-23(39)18(36)16(21)34/h2,6,8-39H,3-5H2,1H3/t6-,8+,9-,10-,11-,12-,13+,14+,15+,16-,17-,18-,19-,20-,21-,22-,23-,24-,25-/m1/s1

InChI key

XUFXOAAUWZOOIT-SXARVLRPSA-N

Gene Information

human ... AMY2A(279), MGAM(8972)

说明

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持，请访问现行药典网站。

Application

阿卡波糖EP参考标准品的预期用途是欧洲药典规定的实验室测试。

Biochem/physiol Actions

作为可逆性α-葡萄糖苷酶抑制剂的改性四糖。

Packaging

本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。

Other Notes

可能适用相应的销售限制。

Still not finding the right product?

Explore all of our products under 阿卡波糖

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.

Matteo Monami et al.

Advances in therapy, 29(9), 736-746 (2012-08-28)

Lipid profile is an important determinant of cardiovascular risk in type 2 diabetes. It is well known that patients with type 2 diabetes are more likely to be dyslipidemic than the general population. Given the observed connection between glucose and

Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.

Sophie Delorme et al.

Current opinion in pharmacology, 5(2), 184-189 (2005-03-23)

The prevalence of glucose intolerance is increasing dramatically worldwide. Both impaired glucose tolerance (IGT) and type 2 diabetes are associated with excess mortality from cardiovascular disease. It is now generally accepted that these cardiovascular complications are related to prevailing hyperglycemia

Postprandial reactive hypoglycaemia in a very old patient.

C Deliens et al.

Acta clinica Belgica, 69(4), 290-293 (2014-06-12)

Postprandial reactive hypoglycaemia (PRH) is a clinical syndrome characterized by the recurrence of symptomatic hypoglycaemia during postprandial periods. PRH remains a diagnostic challenge for clinicians, because of its atypical manifestations and low prevalence, especially in older persons. We report the

查看所有相关文献

全球贸易项目编号

货号	GTIN
Y0000500	04061837568770